One of the biggest challenges in cancer care is that the same therapy can be highly effective for some patients yet fail entirely for others. A new study published in Nature Communications, led by Dr. Louise Fets at the MRC Laboratory of Medical Sciences (LMS), takes a closer look at why this happens. The researchers focused on PARP inhibitors, a class of targeted cancer drugs, and tracked how they move through ovarian tumor samples using advanced imaging tools.
Their findings show that these drugs can accumulate inside lysosomes, small structures within cells that act as “recycling centers.” Once inside, the drugs can become trapped and later released, influencing how well the treatment performs.
Mapping How Cancer Drugs Spread Inside Tumors
Cancer treatment options have expanded rapidly in recent years, improving…